Drugs / 2LVERU®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03977753 | Feb 2020 → Dec 2026 expected | common wart, plantar wart | Labo'Life | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2LVERU | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03977753 ↗ |
| Route | Oral | “taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach” NCT03977753 ↗ |